RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100

Benzinga · 1d ago
RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $95 to $100.